Overview

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Status:
Not yet recruiting

Trial end date:
2023-09-06

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation (formed from cells that release hormones into the blood in response to a signal from the nervous system) that has spread to other places in the body (metastatic). Radioactive drugs, such as lutetium Lu 177, may carry radiation directly to tumor cells and not harm normal cells.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Lutetium Lu 177 dotatate